New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
09:02 EDTENDP, BDSIBioDelivery Sciences could be bought by Endo, says Summer Street
Summer Street sees shares of BioDelivery Sciences (BDSI) heading to the $15 level on positive buprenorphine data in July, a drug the company partners with Endo (ENDP). The firm notes Endo could owe up to $70M in milestones to BioDelivery, but it finds it more likely that Endo buys BioDelivery outright. Summer Street keeps a Buy rating on the stock with a $20 price target.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 20, 2015
08:09 EDTENDPBioSpecifics announces approval of Xiaflex in Japan
Subscribe for More Information
July 17, 2015
10:05 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:38 EDTENDPLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information
06:43 EDTENDPEndo upgraded to Top Pick from Outperform at RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use